BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives $14.67 Consensus Target Price from Brokerages

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) have been assigned an average rating of “Moderate Buy” from the six research firms that are currently covering the company, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $14.67.

Several research analysts have weighed in on BCRX shares. JMP Securities raised their price objective on shares of BioCryst Pharmaceuticals from $15.00 to $16.00 and gave the stock a “market outperform” rating in a research report on Tuesday, August 6th. Barclays lifted their price target on BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the stock an “equal weight” rating in a report on Tuesday, November 5th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $10.00 price target on shares of BioCryst Pharmaceuticals in a research note on Tuesday, November 5th. Needham & Company LLC reiterated a “buy” rating and set a $14.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday, November 5th. Finally, HC Wainwright restated a “buy” rating and issued a $30.00 target price on shares of BioCryst Pharmaceuticals in a research report on Tuesday, August 6th.

BioCryst Pharmaceuticals Stock Performance

Shares of NASDAQ:BCRX opened at $7.03 on Friday. BioCryst Pharmaceuticals has a 52-week low of $4.03 and a 52-week high of $8.88. The company has a market capitalization of $1.46 billion, a P/E ratio of -11.52 and a beta of 1.89. The company has a 50-day simple moving average of $7.70 and a 200 day simple moving average of $7.12.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its earnings results on Monday, November 4th. The biotechnology company reported ($0.07) EPS for the quarter, hitting the consensus estimate of ($0.07). The business had revenue of $117.10 million for the quarter, compared to the consensus estimate of $113.99 million. During the same quarter in the prior year, the firm posted ($0.19) earnings per share. The business’s revenue was up 35.1% compared to the same quarter last year. As a group, equities analysts forecast that BioCryst Pharmaceuticals will post -0.38 earnings per share for the current year.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the stock. CWM LLC increased its position in BioCryst Pharmaceuticals by 200.0% in the 2nd quarter. CWM LLC now owns 5,658 shares of the biotechnology company’s stock valued at $35,000 after acquiring an additional 3,772 shares during the period. Signaturefd LLC grew its stake in shares of BioCryst Pharmaceuticals by 560.5% in the second quarter. Signaturefd LLC now owns 6,598 shares of the biotechnology company’s stock worth $41,000 after purchasing an additional 5,599 shares during the last quarter. Seven Eight Capital LP bought a new position in BioCryst Pharmaceuticals during the 1st quarter worth $57,000. Mirae Asset Global Investments Co. Ltd. raised its position in BioCryst Pharmaceuticals by 21.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,483 shares of the biotechnology company’s stock worth $57,000 after purchasing an additional 1,322 shares during the last quarter. Finally, Natixis grew its position in shares of BioCryst Pharmaceuticals by 400.6% in the 1st quarter. Natixis now owns 11,684 shares of the biotechnology company’s stock valued at $59,000 after buying an additional 9,350 shares during the last quarter. 85.88% of the stock is currently owned by institutional investors and hedge funds.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.